BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Neoplasms
DRUG: Copanlisib (Aliqopa, BAY80-6946)
Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response., 2 years
Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes., 2 years|Evaluate for early signs of efficacy in expansion cohorts, 2 years
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.